Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taltzcept plus conventional therapy in pediatric IgA vasculitis nephritis
ChiCTR2600128049Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Jul 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of telitacicept in IgA vasculitis nephritis (2 arms), sponsored by Peking University First Hospital. Primary endpoint: Remission rate of urinary protein at 24 weeks. Started Jul 2026; status: recruiting.
02
Drugs
telitacicept
03
Conditions
IgA vasculitis nephritis
Beyond the preview
Go deeper on ChiCTR2600128049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128049.